ATE455560T1 - Topische zusammensetzungen enthaltend einen alpha 1-adrenergic blocker zur behandlung von schmerzhaften zuständen der analregion - Google Patents

Topische zusammensetzungen enthaltend einen alpha 1-adrenergic blocker zur behandlung von schmerzhaften zuständen der analregion

Info

Publication number
ATE455560T1
ATE455560T1 AT99909618T AT99909618T ATE455560T1 AT E455560 T1 ATE455560 T1 AT E455560T1 AT 99909618 T AT99909618 T AT 99909618T AT 99909618 T AT99909618 T AT 99909618T AT E455560 T1 ATE455560 T1 AT E455560T1
Authority
AT
Austria
Prior art keywords
painful conditions
anal region
alpha
treatment
compositions containing
Prior art date
Application number
AT99909618T
Other languages
English (en)
Inventor
Barry Fogel
Original Assignee
Synchroneuron Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE455560(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synchroneuron Llc filed Critical Synchroneuron Llc
Priority claimed from PCT/US1999/004158 external-priority patent/WO1999043354A2/en
Application granted granted Critical
Publication of ATE455560T1 publication Critical patent/ATE455560T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99909618T 1998-02-27 1999-02-25 Topische zusammensetzungen enthaltend einen alpha 1-adrenergic blocker zur behandlung von schmerzhaften zuständen der analregion ATE455560T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/031,858 US6159944A (en) 1998-02-27 1998-02-27 Method for treating painful conditions of the anal region and compositions therefor
US09/258,828 US6117877A (en) 1998-02-27 1999-02-25 Method for treating painful conditions of the anal region and compositions therefor
PCT/US1999/004158 WO1999043354A2 (en) 1998-02-27 1999-02-25 Method for treating painful conditions of the anal region and compositions therefor

Publications (1)

Publication Number Publication Date
ATE455560T1 true ATE455560T1 (de) 2010-02-15

Family

ID=21861782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909618T ATE455560T1 (de) 1998-02-27 1999-02-25 Topische zusammensetzungen enthaltend einen alpha 1-adrenergic blocker zur behandlung von schmerzhaften zuständen der analregion

Country Status (3)

Country Link
US (2) US6159944A (de)
AT (1) ATE455560T1 (de)
DE (1) DE69941949D1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537773B1 (en) * 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
US6627632B2 (en) 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6391869B1 (en) * 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20030054020A1 (en) * 2001-09-07 2003-03-20 Sarfaraz Niazi Method and composition for reducing sebum secretion in mammals
EP1443932B1 (de) * 2001-11-15 2012-12-26 Micro Algae Corporation Pharmazeutische zusammensetzungen mit 3,4-propinoperhydropurinen und ihre verwendung zur blockierung der neuronalen übertragung
US6620852B2 (en) * 2001-12-17 2003-09-16 Gerald Brogan Topical anesthetic
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US20040076671A1 (en) * 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment
US20040127861A1 (en) * 2002-12-26 2004-07-01 Bradley Pharmaceuticals, Inc. Method and apparatus for dispensing a composition
WO2004071447A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
BRPI0414277A (pt) * 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7414039B2 (en) * 2004-01-28 2008-08-19 The Regents Of The University Of California Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US8211871B2 (en) * 2005-10-31 2012-07-03 Coloplast A/S Topical skin barriers and methods of evaluation thereof
US8258191B2 (en) * 2005-10-31 2012-09-04 Coloplast A/S Topical skin barriers and methods of evaluation thereof
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
AU2007211319B9 (en) * 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
US20080038377A1 (en) * 2006-08-09 2008-02-14 Citow Jonathan S Device for treatment of inflamed tissue
US20090023637A1 (en) * 2006-08-30 2009-01-22 Parsons C Lowell Methods for detecting and treating interstitial cystitis
US10143694B2 (en) 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
US20090163509A1 (en) * 2006-10-27 2009-06-25 Kopacki Matthew H Method for healing a wound using an alpha-adrenergic antagonist
WO2011057387A1 (en) * 2009-11-13 2011-05-19 Oral Delivery Technology Ltd . Nitric oxide amino acid esters for the treatment of chronic pain
EP2329849B1 (de) 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
AR083651A1 (es) 2010-10-21 2013-03-13 Galderma Sa Composiciones de brimonidina en gel y metodos de uso
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140235570A1 (en) * 2013-02-19 2014-08-21 David Jonathan Hochman Therapeutic composition for the treatment of perianal disorders
WO2017132214A1 (en) * 2016-01-26 2017-08-03 Scherer Warren J Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945084A (en) * 1987-07-08 1990-07-31 Norman Oksman Method and composition for topically treating anorectal or other dermal wounds
US5447947A (en) * 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
AU2282395A (en) * 1994-05-27 1995-12-21 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5854291A (en) * 1996-04-23 1998-12-29 Medical Merchandising, Inc. Pain reliever and method of use

Also Published As

Publication number Publication date
US6159944A (en) 2000-12-12
DE69941949D1 (de) 2010-03-11
US6117877A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
ATE455560T1 (de) Topische zusammensetzungen enthaltend einen alpha 1-adrenergic blocker zur behandlung von schmerzhaften zuständen der analregion
WO1999043354A3 (en) Method for treating painful conditions of the anal region and compositions therefor
DE69905938D1 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
ATE430573T1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
FI973492A0 (fi) NO-syntaasin estäjät
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
GB9807639D0 (en) Anti-inflammatory agents
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
DE69738667D1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
PT969843E (pt) Composicoes antitussicas contendo teobromina
ES2087160T3 (es) Composiciones y procedimiento para el tratamiento de trastornos dolorosos, inflamatorios o alergicos.
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
DK227090D0 (da) Organisk guldkompleks til topisk anvendelse
CA2591917A1 (en) Analgesic compositions for treating painful conditions of the anal region and uses thereof
PT966286E (pt) Atenuacao da tolerancia aos opioides por inibicao das vias de sintase de oxido nitrico induziveis no tratamento da dor
UA36485A (uk) Спосіб лікування генералізованого пародонтиту

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties